000			03729nam a22003255i 4500
999			_c402791 _d402791
001			402791
003			ES-MaUEC
005			20240629192749.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			231107s2023 sz | fo |||| 0|eng d
020			_a9783031386237
024	7		_a10.1007/978-3-031-38623-7 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280 .P25 _b2023 EB
245	0	0	_aPancreatic Cancer : _bCurrent Therapeutics and Future Directions _cedited by Shubham Pant
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aResectable Pancreatic Cancer: Neoadjuvant and Adjuvant Therapy -- Borderline Resectable and Locally Advanced Pancreatic Cancer -- Radiation Therapy for Pancreatic Cancer: Current and Evolving Paradigms -- Therapies for Metastatic Pancreatic Cancer -- Targeted Therapies for Pancreatic Cancer -- Immunotherapy for Pancreatic Cancer -- Liquid Biopsies for pancreatic cancer: Is it ready for prime time? -- Supportive Care challenges and management in Pancreatic Cancer -- Physical activity and nutrition optimization in pancreatic cancer.
520			_a Pancreatic cancer is a challenging and complex disease characterized by a dense fibrotic stroma and an immunosuppressive tumor microenvironment. Until recently, there were no predictive biomarkers to personalize selection of targeted or biologic therapies as a part of standard of care treatment. Moreover, the regulatory immune population of cells creates a "cold", non-immunogenic tumor that is resistant to immunotherapies including checkpoint inhibitors. However, in the last few years, there has been substantial progress in our understanding of the role mutations in the pathogenesis of disease leading to increased adoption of germline and next generation sequencing to identify mutations and fusions to optimize selection of therapies and select patients for clinical trials of targeted agents. This book provides a comprehensive, global overview on therapy for pancreatic cancer, exploring approved therapies and focusing on the "Next" in drug development including molecularly targeted therapy and efforts at "Drugging the Undruggable": the KRAS mutation. It also addresses efforts at targeting the inhospitable stroma to improve drug delivery to the tumor cells, incorporating ct DNA (liquid biopsies) in the care of patients and recent advances in immunotherapy. Pancreatic Cancer: Current Therapeutics and Future Directions will illuminate these challenges, review existing therapeutics, and highlight current and future efforts to improve outcomes in this devastating disease. Useful to physicians, fellows, medical students, residents, physician assistants, nurse practitioners, pharmaceutical companies and researchers interested in pancreatic cancer, it will first explain management of localized disease including resectability and adjuvant and neoadjuvant therapies. Targeted therapies including molecular, immunotherapy, stroma and role of ctDNA or "liquid biopsies" will be addressed. Finally, the book will explore the important role of pain management, diet and exercise in improving outcomes in pancreatic cancer.
988			_aSpringer_Medicine_2023
650		7	_2embne _9194247 _aPáncreas _xCáncer _xTratamiento
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-38623-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b06/2024 _dz _ean _zSI